research Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
Restoring hair bulb immune privilege is crucial for managing alopecia areata.
Search
for
Sort by
Research
120-150 / 358 results 
research Treatment of Alopecia Areata: An Australian Expert Consensus Statement
Alopecia areata treatment varies, with no optimal method established yet.
research Human αβ and γδ T Cells in Skin Immunity and Disease
Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.
research Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research Understanding Autoimmunity of Vitiligo and Alopecia Areata
Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
research The Emerging Role of Janus Kinase Inhibitors in the Treatment of Autoimmune and Inflammatory Diseases
Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
research Drug Discovery for Alopecia: Gone Today, Hair Tomorrow
Topical drugs and near-infrared light therapy show potential for treating alopecia.
research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research The Role of Lymphocytes in the Development and Treatment of Alopecia Areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research Unmet Medical Needs in Chronic, Non-Communicable Inflammatory Skin Diseases
There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
research Functional Complexity of Hair Follicle Stem Cell Niche and Therapeutic Targeting of Niche Dysfunction for Hair Regeneration
Understanding how hair follicle stem cells work can help find new ways to prevent hair loss and promote hair growth.
research Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity
Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
research Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options
The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
research Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients
Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
research Selected Disorders of Skin Appendages: Acne, Alopecia, Hyperhidrosis
The conclusion is that acne, alopecia, and hyperhidrosis are common skin issues with various treatments available, and accurate diagnosis is key for effective management.
research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Common Causes of Hair Loss: Clinical Manifestations, Trichoscopy, and Therapy
The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.
research Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Baricitinib: From Rheumatoid Arthritis to COVID-19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research Bimatoprost for the Treatment of Eyelash, Eyebrow, and Scalp Alopecia
Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.
research Alopecia Areata: Current Situation and Perspectives
Alopecia Areata is a complex, unpredictable autoimmune hair loss condition with limited treatment options and a significant psychological impact.
research The Influence of Interferon on Healthy and Diseased Skin
Type I interferons play a key role in the development of various skin diseases.
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction
Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
research Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata
Regenerative therapies show promise for treating vitiligo and alopecia areata.
research Cholesterol Homeostasis: Links to Hair Follicle Biology and Hair Disorders
Cholesterol balance is important for hair health, and problems with it can lead to hair loss conditions.
research A Pilot Study of 2% Tofacitinib Cream with Narrowband Ultraviolet B for the Treatment of Facial Vitiligo
Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.